portal hypertension
Conditions
Interventions
2:20mg long-acting octreotide muscular injection mon
3:40mg long-acting octreotide muscular injection mon
Sponsors
Shanghai Sixth People's Hospital
Eligibility
Sex/Gender
All
Age
45 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. absence of documented hepatocellular carcinoma; 2. no decompensated cardiorespiratory disease; 3. no infection; 4. no treatment with somatostatin or any synthetic analog in the previous six weeks and no known hypersensitivity reaction to octreotide; 5. no severe coagulopathy (prothrombin > 40% and platelets > 50 g/L); 6. declared abstinence from alcohol; 7. moderate to severe liver failure with liver cirrhosis (Pughs score: 7–10); 8. history of esophageal varices assessed by endoscopic observation; 9. suffered from rebleeding despite undergoing repeated endoscopic variceal ligation; 10. began taking a beta blocker (non-selective) at the time of first variceal ligation, during which dose was adjusted to reduce baseline heart rate by 25% or to reach a pulse rate of 55/min; 11. currently using the same beta blocker to prevent variceal rebleeding and remained on the agent for the duration of the study period; 12. no current use of any other drug therapy known to have an influence on portal pressure.
Exclusion criteria
Exclusion criteria: 1. Hpatocellular carcinoma; 2. Cmplited with cardiorespiratory disease; 3. Infection; 4. Treated by somatostatin or any synthetic analog and known hypersensitivity reaction to octreotide; 5. severe coagulopathy (prothrombin >40% and platelets >50 G/L); 6. abstinence from alcohol;7.currently use of any other drug therapy except beta-blockers known to have an influence on portal pressure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HVPG (mmHg);VEGF (pg/mL); | — |
Countries
China
Contacts
Public ContactGuang-Wen Zhou
Outcome results
None listed